XML 60 R36.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-Based Compensation (Tables)
12 Months Ended
Dec. 31, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Schedule of Restricted Stock Award Activity

The following summarizes restricted stock award activity:

 

 

Number of
Shares
Outstanding

 

 

Weighted-
Average
Grant Date
Fair Value
Per Share

 

Balance at December 31, 2023

 

 

1,002,044

 

 

$

2.67

 

Restricted stock awards vested

 

 

(410,916

)

 

 

2.77

 

Restricted stock awards repurchased

 

 

(14,299

)

 

 

2.31

 

Balance at December 31, 2024

 

 

576,829

 

 

 

2.62

 

 

Summary of Weighted Average Assumptions used for Grants Awards

The weighted-average assumptions used to value employee and non-employee stock option awards granted during the years ended December 31, 2024 and 2023, using the Black Scholes option pricing model, were as follows:

 

 

Years Ended December 31,

 

 

2024

 

 

2023

 

Fair value of common stock

 

$

6.65

 

 

$

3.01

 

Risk-free interest rate

 

 

3.83

%

 

 

4.56

%

Expected volatility

 

 

91.1

%

 

 

86.2

%

Expected term (years)

 

 

6.03

 

 

 

5.90

 

Expected dividend yield

 

%

 

 

%

 

 

Summary Of Stock Based Compensation Expense For Restricted Stock Awards And Stock Options

Stock-based compensation expense for restricted stock awards and stock options recognized in the Company’s statements of operations and comprehensive (loss) income is presented as follows (in thousands):

 

 

Years Ended December 31,

 

 

2024

 

 

2023

 

Research and development expense

 

$

1,619

 

 

$

887

 

General and administrative expense

 

 

1,533

 

 

 

733

 

Total stock-based compensation expense

 

$

3,152

 

 

$

1,620

 

2024 and 2021 Plan [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Schedule of Stock Options Activity

The following summarizes stock option activity under the 2024 and 2021 Plans:

 

 

Options Outstanding

 

 

Total
Options
Outstanding

 

 

Weighted-
Average
Exercise
Price

 

 

Weighted-
Average
Remaining
Contractual
Life

 

 

Aggregate
Intrinsic
Value

 

 

 

 

 

 

 

 

(in years)

 

 

(in thousands)

 

Outstanding as of December 31, 2023

 

 

1,123,296

 

 

$

2.62

 

 

 

9.78

 

 

$

2,287

 

Granted

 

 

1,965,907

 

 

 

5.66

 

 

 

 

 

 

 

Exercised

 

 

(28,896

)

 

 

2.28

 

 

 

 

 

 

 

Cancelled

 

 

(121,325

)

 

 

3.02

 

 

 

 

 

 

 

Outstanding as of December 31, 2024

 

 

2,938,982

 

 

 

4.64

 

 

 

9.11

 

 

 

53,706

 

Exercisable as of December 31, 2024

 

 

514,144

 

 

 

2.90

 

 

 

8.23

 

 

 

10,285